Published Research and Presentations

An international r andomi z ed phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP protocol 1302)

P3BEP

22/02/2023

DZebic, M Stockler A Martin F Pashankar, B Tran D Mazhar, R Huddart, M Wheater, E Walpole, E Dunwoodie, DR Feldman, A Birtle AG Stevanovic, D Wyld, FJ Hanning, P SGrimison

DASL-HiCaP: Darolutamide Augments Standard therapy for Localized very High-risk Cancer of the Prostate – a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801

DASL-HiCaP

22/02/2023

T Niazi SM McBride, S Williams, ID Davis, MR Stockler AJ Martin, HT Chung, FT Roncolato, A Ebacher, E Khoo, J Martin, TS Lim, S Hughes, D Pryor, J Catto, P Kelly, LG Rezaei, SC Morgan, R Rendon, CJ Sweeney

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP ANZUP 1603): a biomarker analysis from a randomised, open-label, phase 2 trial

TheraP

EANM’22 Annual Congress

31/10/2022

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman

PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER ANALYSIS OF SAFETY AND EFFICACY OF THE PCR-MIB PHASE II CLINICAL TRIAL (ANZUP 1502)

PCR MIB

ESMO

13/09/2022

A. Weickhardt, F. Foroudi, N. Lawrentschuk, Jing Xie, Komal Konijia, Mark Sidhom, Abhijit Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, M. McJannett, C. Conduit, B. Tran,I.D Davis, D. Hayne, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group(ANZUP)

P3 BEP: Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (ANZUP protocol 1302)

P3BEP

MOGA 2022

19/08/2022

D Zebic, M Stockler, A Martin, F Pashankar, B Tran, D Mazhar, R Huddart, M Wheater, E Walpole, E Dunwoodie, D Feldman, A Birtle, AG Stevanovic, D Wyld, FJ Hanning, PS Grimison, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: overall survival after median follow-up of 3 years (TheraP ANZUP protocol 1603).

TheraP

ASCO 2022

05/06/2022

Michael Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn Francis, Craig Gedye, Natalie Rutherford, Andrew Scott, Alison Zhang, Margaret McJannett, Martin Stockler, Scott Williams, Andrew Martin, Ian D. Davis, on behalf of the TheraP Investigators

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormonesensitive prostate cancer (mHSPC)

ENZAMET

ASCO 2022

05/06/2022

Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN,Pook DW, Parnis F, North SA, Marx GM, McCaffrey J, McDermott R, Lawrence NJ, Horvath L, Frydenberg M, Chowdhury S, Chi KN, Stockler MR, Sweeney CJ,on behalf of the ENZAMET Investigators

Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma

UNISoN

ASCO 2022

04/06/2022

C Gedye, D Pook, L Krieger, C Harris, J C Goh, G Kichenadasse, H Gurney, C Underhill, F Parnis, A M Joshua, T Ferguson, F T Roncolato, M Harrison, M Morris, S Begbie, E Hovey, M George, P Prithviraj, E Link, I D Davis, on behalf of The Australian and New Zealand Urogenital and Prostate Cancer Trials Group

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate –a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801)

DASL-HiCaP

ASCO 2022

03/06/2022

T Niazi1, S M McBride, S Williams, I D Davis, M R Stockler, A J Martin, L Horvath, S Sengupta, J Martin, T S Lim, S Hughes, R McDermott, J Catto, P Kelly, W Parulekar, K Bracken, F T Roncolato, S C Morgan, R Rendon and C J Sweeney, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).

TheraP

ASCO GU 2022

19/02/2022

James Patrick Buteau, Andrew James Martin, Louise Emmett, Amir Iravani, Shahneen Kaur Sandhu, Anthony M. Joshua, Alison Yan Zhang, Roslyn J. Francis, Andrew Mark Scott, Arun Azad, Margaret Mary McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S Hofman